We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00057551
Recruitment Status : Completed
First Posted : April 7, 2003
Results First Posted : June 10, 2016
Last Update Posted : December 6, 2017
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Depression
Depressive Disorder
Interventions: Behavioral: Brief Supportive Psychotherapy
Behavioral: CBASP
Drug: Medication Only

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
CBASP Cognitive Behavioral Analysis System of Psychotherapy
BriefSP Brief Supportive Psychotherapy
Medication Only

An algorithm including Sertraline, Escitalopram

Bupropion SR or XL

Venlafaxine XR


Participant Flow:   Overall Study
    CBASP   BriefSP   Medication Only
STARTED   200   195   96 
COMPLETED   175   168   80 
NOT COMPLETED   25   27   16 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
CBASP Cognitive Behavioral Analysis System of Psychotherapy
Brief Supportive P Brief Supportive Psychotherapyherapy
Medication Only



Bupropion SR or XL

Venlafaxine XR


Total Total of all reporting groups

Baseline Measures
   CBASP   Brief Supportive P   Medication Only   Total 
Overall Participants Analyzed 
[Units: Participants]
 200   195   96   491 
[Units: Years]
Mean (Standard Deviation)
 43.2  (13.4)   46.4  (11.7)   45.3  (11.9)   45.9  (11.8) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      112  56.0%      113  57.9%      47  49.0%      272  55.4% 
Male      88  44.0%      82  42.1%      49  51.0%      219  44.6% 
Region of Enrollment 
[Units: Participants]
United States   200   195   96   491 
Hamilton Depression Scale [1] 
[Units: Units on a scale]
Mean (Standard Deviation)
 19.52  (8.26)   19.44  (8.31)   18.4  (8.8)   19.48  (8.27) 
[1] Scores range from 0-72 with higher scores indicating more severe depression

  Outcome Measures

1.  Primary:   Remission   [ Time Frame: 12 weeks ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: James H. Kocsis, M.D.
Organization: Weill Cornell Medical College
phone: 212-746-5913
e-mail: jhk2002@med.cornell.edu

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT00057551     History of Changes
Other Study ID Numbers: U01MH062475 ( U.S. NIH Grant/Contract )
U01MH061504 ( U.S. NIH Grant/Contract )
U01MH061562 ( U.S. NIH Grant/Contract )
U01MH061587 ( U.S. NIH Grant/Contract )
U01MH061590 ( U.S. NIH Grant/Contract )
U01MH062465 ( U.S. NIH Grant/Contract )
U01MH062491 ( U.S. NIH Grant/Contract )
U01MH062546 ( U.S. NIH Grant/Contract )
U01MH063481 ( U.S. NIH Grant/Contract )
First Submitted: April 4, 2003
First Posted: April 7, 2003
Results First Submitted: April 7, 2015
Results First Posted: June 10, 2016
Last Update Posted: December 6, 2017